Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus

Table 1 Characteristics of hepatitis B e antigen-negative chronic hepatitis B children

Characteristic
n	52
Age (yr)
Median (range)	16 (4-18)
Gender
Female/male	16 (30.8)/36 (69.2)
Staging (F)
F0/F1/F2/F3	2 (3.9)/31 (59.6)/16 (30.7)/3 (5.8)
Grading (A)
A0/A1/A2	2 (3.9)/ 22 (42.3)/28 (53.8)
IL28B SNPs
rs12979860 CC/CT/TT	20 (38.5)/26 (50.0)/6 (11.5)
rs12980275 AA/AG/GG	24 (46.2)/24 (46.2)/4 (7.6)
rs8099917 TT/TG/GG	30 (57.7)/19 (36.5)/3 (5.8)
OAS SNPs
rs10849829 AA/AG/GG	19 (36.5)/27 (52.0)/6 (11.5)
rs1131476 AA/AG/GG	26 (50.0)/17 (32.7)/9 (17.3)
rs1293747 GG/GA/AA	32 (61.5)/17 (32.7)/3 (5.8)
rs2072136 GG/GA/AA	30 (57.7)/20 (38.5)/2 (3.8)
Baseline HBV DNA (IU/mL)
median (range), log	4.6 (3.4-8.0)
< 20000	31 (59.6)
Baseline ALT (U/L)
median (range)	42 (12-210)
< 40	14 (26.9)
At week 24 of treatment
HBV DNA < 100 (IU/mL)	32 (61.5)
ALT < 40 (U/L)	13 (25.0)
At the end of treatment
HBV DNA < 2000 (IU/mL)	39 (75.0)
ALT < 40 (U/L)	28 (53.9)
24 wk post-treatment
HBV DNA < 2000 (IU/mL)	27 (51.92)
ALT < 40 (U/L)	37 (71.15)
Partial response
< 2000 IU/mL HBV DNA or < 40 IU/L ALT	42 (80.8)
Complete response
< 2000 IU/mL HBV DNA with < 40 IU/L ALT	22 (42.3)

Data are presented as the number of patients (%) unless otherwise indicated.